Virax Biolabs (VRAX) Shares Outstanding (Weighted Average) (2021 - 2023)

Virax Biolabs (VRAX) has 3 years of Shares Outstanding (Weighted Average) data on record, last reported at $10.6 million in Q1 2023.

  • For Q1 2023, Shares Outstanding (Weighted Average) rose 11.15% year-over-year to $10.6 million; the TTM value through Mar 2023 reached $10.6 million, up 11.15%, while the annual FY2023 figure was $10.6 million, 11.15% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $10.6 million in Q1 2023 per VRAX's latest filing, up from $9.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $10.6 million in Q1 2023 and bottomed at $1.6 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 3 years is $7.3 million, with a median of $9.6 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 504.72% in 2022, then increased 11.15% in 2023.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $1.6 million in 2021, then skyrocketed by 504.72% to $9.6 million in 2022, then rose by 11.15% to $10.6 million in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $10.6 million in Q1 2023, $9.6 million in Q1 2022, and $1.6 million in Q1 2021.